TABLE 3.

Association of bone mineral density Z-score changes from diagnosis to week 120 with dexamethasone and methotrexate pharmacokinetics and albumin, lipid, and cortisol levels

Variables	N	Individual factora			Multiple linear regressionb
		Coefficient	95% CI	P	Coefficient	95% CI	P
Average of dexamethasone AUCs in weeks 7 and 8 of continuation	241	−0.070	−0.094 to −0.046	<0.001	−0.047	−0.073 to −0.021	<0.001
Average methotrexate AUCs during consolidation	276	−0.025	−0.036 to −0.013	<0.001	−0.025	−0.052 to 0.001	0.062
Albumin level (g/dL) in week 7 of continuation	263	0.512	0.313 to 0.711	<0.001	0.342	0.063 to 0.622	0.017
Triglyceride level (mg/dL) in week 7 of continuation	250	−0.038	−0.054 to −0.021	<0.001	−0.021	−0.038 to −0.003	0.021
Total cholesterol level (mg/dL) in week 7 of continuation	250	−0.122	−0.183 to −0.061	<0.001	−0.073	−0.134 to −0.013	0.018
LDL level (mg/dL) in week 7 of continuation	250	−0.037	−0.120 to 0.047	0.394	−0.035	−0.115 to 0.045	0.396
HDL level (mg/dL) in week 7 of continuation	250	0.135	−0.034 to 0.305	0.119	−0.004	−0.169 to 0.161	0.961
Cortisol level (μg/dL) in week 7 of continuation	263	0.017	−0.003 to 0.037	0.101	0.007	−0.012 to 0.026	0.468

^aP-value after adjustment for bone mineral density Z-score at diagnosis and race

^bP-value after adjustment for bone mineral density Z-score at diagnosis, race, age, and treatment risk

Average of dexamethasone AUCs in weeks 7 and 8 was evaluated for the change of 50 nM*h, and triglyceride, total cholesterol, LDL, and HDL levels were examined for each increment of 20 mg/dL.

Abbreviations: CI, confidence interval; AUC, area under the plasma drug concentration–time curve; LDL, low-density lipoprotein; HDL, high-density lipoprotein